Centaur Pharmaceuticals Private Limited

Centaur Pharmaceuticals Private Limited, established on October 15, 1980, is a privately held Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24230MH1980PTC023291. As of the latest available data, Centaur Pharmaceuticals has an authorized share capital of ₹200 million and a paid-up capital of ₹184.96 million. The company employs approximately 2,700 individuals, reflecting its significant presence in the pharmaceutical industry. Centaur Pharmaceuticals operates across various segments, including Active Pharmaceutical Ingredients (API), formulations, Contract Research and Manufacturing Services (CRAMS), Clinical Research, Research and Development (R&D), regulatory affairs, and marketing.

Centaur Pharmaceuticals operates multiple manufacturing facilities to cater to diverse market needs. The Goa facility, approved by the U.S. Food and Drug Administration (FDA), specializes in the production of Sinarest, India's leading anti-cold medication. This facility has been recognized for its marketing excellence, winning the 'Brand of the Year for Marketing Excellence' seven times consecutively. Additionally, Centaur has a fully scalable 25,000-square-meter finished dosage formulations facility in Pune, designed to serve international markets. This facility boasts an annual capacity of 3 billion tablets and 600 million capsules, housing both formulations R&D and analytical development sections.

The leadership team at Centaur Pharmaceuticals includes:

• Shivanand Dattatraya Sawant: Managing Director since October 15, 1980.

• Sharadchandra Damodar Abhyankar: Director since August 11, 2016.

• Albert Taura: Director since August 11, 2016.

• Smita Abhayakumar Phal: Whole-Time Director since June 22, 2011.

• Rakhi Shridhar Kadam: Whole-Time Director since September 14, 2015.

• Supriya Samar Desai: Whole-Time Director since December 21, 2021.

Centaur Pharmaceuticals has established a presence in several regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. The Goa facility's approval by the U.S. FDA underscores the company's commitment to meeting stringent international standards. However, in June 2023, the FDA issued a warning letter to Centaur Pharmaceuticals, citing deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API) at their Ambernath facility. The letter highlighted issues such as inadequate document control and failure of the quality unit to ensure compliance with CGMP. This incident may impact the company's standing in other regulated markets, necessitating prompt corrective actions to maintain market access.

Centaur Pharmaceuticals has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's portfolio includes 57 APIs, with 38 being pioneered for the first time in India, indicating a strong focus on innovation. Additionally, Centaur has developed a new chemical entity, Woxheal, for the treatment of diabetic foot ulcers, demonstrating its commitment to addressing unmet medical needs. While the company has not explicitly stated WHO prequalification for its products, its active engagement in these regions suggests a strategic approach to penetrating emerging markets.

Centaur Pharmaceuticals' geographic strategy appears to be focused on diversification, with exports to 96 countries across five continents. This broad reach indicates a deliberate effort to mitigate concentration risk by tapping into various regional markets. The company's strong presence in Asia, South America, and Africa aligns with its strategic direction to leverage growth opportunities in emerging markets. However, the recent FDA warning letter may necessitate a reassessment of its strategies in certain regions to ensure sustained growth and compliance.

Centaur Pharmaceuticals' manufacturing facilities are registered with the FDA, indicating compliance with U.S. regulations. However, the June 2023 warning letter from the FDA highlights significant deviations from CGMP at their Ambernath facility, including inadequate document control and failure of the quality unit to ensure compliance with CGMP. This incident underscores the importance of stringent quality control measures and may impact the company's ability to maintain or expand its market presence in the U.S.

Centaur Pharmaceuticals' Goa facility is approved by the U.S. FDA, indicating adherence to international manufacturing standards. The company also holds WHO-GMP certifications for its formulations facilities in Goa, catering to both Indian and international markets. However, there is no explicit information available regarding EU GMP certifications or EDQM status. This lack of certification may limit the company's ability to access certain European markets and could be a consideration for potential partners and customers.

Centaur Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facilities in Goa are WHO-GMP approved, indicating compliance with international standards. However, the June 2023 FDA warning letter highlights deviations from CGMP at their Ambernath facility, which may have implications for their standing with Indian regulatory authorities. The company has not provided explicit information regarding state drug controller approvals or export No Objection Certificates (NOCs), which are essential for international trade.

In June 2023, the FDA issued a warning letter to Centaur Pharmaceuticals, citing significant deviations from CGMP at their Ambernath facility. The letter highlighted issues such as inadequate document control and failure of the quality unit to ensure compliance with CGMP. This regulatory action underscores the importance of stringent quality control measures and may impact the company's ability to maintain or expand its market presence in regulated markets.

Centaur Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. The company's focus on APIs, formulations, and contract manufacturing services positions it alongside other Indian pharmaceutical firms with similar capabilities. However, the recent FDA warning letter may affect Centaur's competitive standing, especially in markets where regulatory compliance is critical. The company's strong presence in emerging markets may provide a competitive edge, but it also faces competition from both local and international companies targeting these regions.

Centaur Pharmaceuticals differentiates itself through its fully integrated operations across the pharmaceutical value chain, including API manufacturing, formulations, clinical research, and contract manufacturing services. The company's focus on innovation is evident in the development of Woxheal, a new chemical entity for the treatment of diabetic foot ulcers. Additionally, Centaur's strong presence in emerging markets and its ability to cater to both domestic and international markets through WHO-GMP approved facilities are notable strengths.

Centaur Pharmaceuticals' current strategic direction encompasses a broad portfolio, including generics, specialty products, and contract manufacturing services. The company's focus on innovation, as demonstrated by the development of Woxheal, indicates a commitment to specialty products. The recent FDA warning letter highlights the need for enhanced quality control measures to maintain and expand its market presence. The company's future outlook will depend on its ability to address regulatory challenges, uphold quality standards, and leverage its strengths in emerging markets.

Centaur Pharmaceuticals has a diverse supplier base, supporting its operations across API manufacturing, formulations, and contract manufacturing services. The company's export volume of $11.1 million USD across 333 shipments indicates a consistent track record in international trade.